Martine Fohlen1, Delphine Taussig2,3, Jerry Blustajn4, Serge Rivera5, Tom Pieper6, Sarah Ferrand-Sorbets2, Georg Dorfmuller2. 1. Pediatric Neurosurgery Department, Rothschild Foundation Hospital, 29 rue Manin, 75019, Paris, France. fohlen.martine@gmail.com. 2. Pediatric Neurosurgery Department, Rothschild Foundation Hospital, 29 rue Manin, 75019, Paris, France. 3. Neurophysiologie Et Epileptologie, Université Paris Saclay-APHP, Le Kremlin Bicêtre, France. 4. Diagnostic Neuroradiology Department, Rothschild Foundation Hospital, Paris, France. 5. Department of Paediatric Neurology, Bayonne Hospital, Bayonne, France. 6. Epilepsy Center for Children and Adolescents, Neuropediatric Clinic and Clinic for Neurorehabilitation, Schoen-Klinik Vogtareuth, Krankenhausstr. 20, D-83569, Vogtareuth, Germany.
Abstract
PURPOSE: Hypothalamic hamartomas (HH) are malformations responsible for drug-resistant epilepsy. HH are usually isolated or part of a genetic syndrome, such as Pallister-Hall. Exceptionally they can be associated with other brain malformations such as polymicrogyria (PMG) and periventricular nodular heterotopia (PNH). We discuss the origin of the seizures associated with this combination of malformations, through electrophysiological studies, and review the literature on this rarely reported syndrome. METHODS: We retrospectively reviewed the patients with HH who had surgery between 1998 and 2020 and selected those with associated focal PMG and PNH, detected on MRIs. All patients had comprehensive clinical evaluation and surface video-EEG and one underwent stereoelectroencephalography (SEEG). RESULTS: Three male patients out of 182 were identified with a mean age at surgery of 7.5 years. MRI showed unilateral focal PMG (fronto-insulo-parietal, fronto-insulo-parieto-opercular, and fronto-insular, respectively) and multiple PNH homolateral to the main HH implantation side. In two patients, there were strong clinical and scalp EEG arguments for seizure onset within the HH. In the third, due to abnormalities on scalp video-EEG in the same area as PMG and the lack of gelastic seizures, SEEG was indicated and demonstrated seizure onset within the hamartoma. With a mean follow-up of 6 years, two patients were seizure-free. CONCLUSION: Our results show that HH is the trigger of epilepsy, which confirms the high epileptogenic potential of this malformation. In patients such as ours, as in those with isolated HH, we recommend to begin by operating the HH independently of seizure semiology or electrophysiological abnormalities.
PURPOSE: Hypothalamic hamartomas (HH) are malformations responsible for drug-resistant epilepsy. HH are usually isolated or part of a genetic syndrome, such as Pallister-Hall. Exceptionally they can be associated with other brain malformations such as polymicrogyria (PMG) and periventricular nodular heterotopia (PNH). We discuss the origin of the seizures associated with this combination of malformations, through electrophysiological studies, and review the literature on this rarely reported syndrome. METHODS: We retrospectively reviewed the patients with HH who had surgery between 1998 and 2020 and selected those with associated focal PMG and PNH, detected on MRIs. All patients had comprehensive clinical evaluation and surface video-EEG and one underwent stereoelectroencephalography (SEEG). RESULTS: Three male patients out of 182 were identified with a mean age at surgery of 7.5 years. MRI showed unilateral focal PMG (fronto-insulo-parietal, fronto-insulo-parieto-opercular, and fronto-insular, respectively) and multiple PNH homolateral to the main HH implantation side. In two patients, there were strong clinical and scalp EEG arguments for seizure onset within the HH. In the third, due to abnormalities on scalp video-EEG in the same area as PMG and the lack of gelastic seizures, SEEG was indicated and demonstrated seizure onset within the hamartoma. With a mean follow-up of 6 years, two patients were seizure-free. CONCLUSION: Our results show that HH is the trigger of epilepsy, which confirms the high epileptogenic potential of this malformation. In patients such as ours, as in those with isolated HH, we recommend to begin by operating the HH independently of seizure semiology or electrophysiological abnormalities.
Authors: K Arita; F Ikawa; K Kurisu; M Sumida; K Harada; T Uozumi; S Monden; J Yoshida; Y Nishi Journal: J Neurosurg Date: 1999-08 Impact factor: 5.115
Authors: Philippe Kahane; Philippe Ryvlin; Dominique Hoffmann; Lorella Minotti; Alim Louis Benabid Journal: Epileptic Disord Date: 2003-12 Impact factor: 1.819
Authors: Michael S Hildebrand; Nicole G Griffin; John A Damiano; Elisa J Cops; Rosemary Burgess; Ezgi Ozturk; Nigel C Jones; Richard J Leventer; Jeremy L Freeman; A Simon Harvey; Lynette G Sadleir; Ingrid E Scheffer; Heather Major; Benjamin W Darbro; Andrew S Allen; David B Goldstein; John F Kerrigan; Samuel F Berkovic; Erin L Heinzen Journal: Am J Hum Genet Date: 2016-07-21 Impact factor: 11.025
Authors: Samuel F Berkovic; Alexis Arzimanoglou; Ruben Kuzniecky; A Simon Harvey; Andre Palmini; Frederick Andermann Journal: Epilepsia Date: 2003-07 Impact factor: 5.864
Authors: J G Hall; P D Pallister; S K Clarren; J B Beckwith; F W Wiglesworth; F C Fraser; S Cho; P J Benke; S D Reed Journal: Am J Med Genet Date: 1980
Authors: Jeremy L Freeman; Lee T Coleman; R Mark Wellard; Michael J Kean; Jeffrey V Rosenfeld; Graeme D Jackson; Samuel F Berkovic; A Simon Harvey Journal: AJNR Am J Neuroradiol Date: 2004-03 Impact factor: 3.825